People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder who have not responded to at least two oral antidepressants. This approval ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...